Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

American Diversified Holdings Corporation (OTC: ADHC) In Final Stage Development and Beta Testing of New ECommerce Platform Focused on CBD Products

American Diversified Holdings Corp.

American Diversified Holdings Corporation (OTC: ADHC) is announced today announce that the company is in the final stages of developing a state-of-the-art e-commerce site offering CBD products under ADHC brand UNIVERSAL WELLNESS. ADHC and its operating division UNIVERSAL WELLNESS previously announced a comprehensive alliance with GGII's leading group of a companies in the CBD and Hemp sector. ADHC's agreement with Green Globe Intl Group (OTC: GGII ), Hempaco (NASDAQ: HPCO ) and GGII's operating subsidiary Green Star Labs provides for a broad range of services and interrelated business activity. The GGII/HEMPACCO/GREENSTAR group has entered into this alliance with ADHC and will collaborate as outlined below: Formulation, manufacturing, private label, inventory management, packaging and shipment logistics with be provided by Green Star Labs under the Universal Wellness and Rolls Choice Brand. Jointly design a line of CDB, Dietary Supplements and Cosmetic products to be offered through ADHC' e-commerce beta platform. Introduce and negotiate endorsement agreements with social media influencers and noted HipHop/Rap luminaries. Hempacco currently has relationships deals with Snoop Dogg Brands, rap artist Rick Ross, Hemp Hop Smokables and Cheech and Chong, Hemp Cigarettes. Parties have agreed to a financial partnership including share issuances, line of credit for product inventory, capital formation and addition of future management. Parties have agreed to assess the develop of ADHC existing brand and future products under development, including products sold under the Rolls Choice Brand of cannabis adhesive pens and Universal Wellness lifestyle and CBD products. This alliance and new ECommerce business is set to springboard ADHC'S branded products into the rapidly growing CDB market sector. A recent report by Market Research Future (MRFR) indicated the CDB market is expected to reach over $59 billion by 2030 an 18% CAGR. See: Cannabidiol (CBD) Market Size Worth USD 59.3 Billion "The GGII/HPCO team is a great alliance partner for ADHC, we can now focus on pushing our brands to the forefront of the CBD and Cannabis markets with a manufacturing and brand building partner that is a dream come true for our shareholder," commented ADHC management. About Hempacco (NASDAQ: HPCO ) Hempacco Co., Inc.'s goal is Disrupting Tobacco's™ nearly $1 trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice, and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff™ functional hemp cigarette and rolling paper brand. Hempacco's operating segments include: Manufacturing of smokables, hemp rolling paper, and cannabinoid sticks Smokable technology development The Real Stuff™ brand of functional smokables and rolling paper Cheech and Chong Hemp Cigarettes and Hemp Hop Smokables with Rick Ross Snoop Dogg Joint Venture of Hemp-Derived Products Learn more at www.hempacco.com. Order products at www.realstuffsmokables.com. About Green Globe International, Inc. (OTC: GGII ): Green Globe International is a Fast-Moving Consumer Goods incubator and holding company of intellectual property, products, and companies that better people's lives by helping them feel and look better inside and out. Green Globe International (GGII) owns or has interests in several brands and companies including; Green Star Labs, Inc., changing how people feel about themselves inside and out with nutritional supplements, CBD, and beauty products, and hemp CBD cigarette and rolling paper manufacturer Hempacco Co. Inc., (NASDAQ: HPCO) Disrupting Tobacco's™ $1 Trillion tobacco industry, with its subsidiaries and joint ventures including HempBox Vending, Inc. a vending and advertising company, Hempacco Paper Company, Inc., producing The Real Stuff Hemp Smokables and hemp paper smoking products like blunts, tubes, and cones, Cali Vibes, Inc. manufacturing cannabinoid cigarettes, HempHop Smokables, Inc., partnering with music producer and rapper Rick Ross, Cheech and Chong Smokables, Inc. delivering cannabinoid Hemp CBD cigarettes to consumers with Cheech and Chong as partners, StickIt USA, Inc., manufacturing a line of cannabinoid sticks, and HPDG, LLC a partnership with Snoop Dogg to develop hemp-derived consumer goods products. Green Globe International is publicly traded under the ticker symbol (OTC: GGII ). It continues to look for best-in-class companies, products, and patents to create Fast Moving Consumer Goods and channels to sell them, including retail automation and advertising platforms. ABOUT ADHC/UNIVERSAL WELLNESS ADHC is a publicly traded holding company trading under the ticker symbol (OTC: ADHC ). ADHC is currently developing two web-based branded businesses. Universal Wellness (UWS) is a wellness and lifestyle e-commerce site focused on providing innovative products, news, and the latest healthcare developments Shares Outstanding: 866 million Shares Restricted: 301 million Shares in the Float: 504 million Investor Contact: Andrew Birnbaum Chairman/CEO CEO@ADHCINVESTOR.com TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. Information contained herein includes forward-looking statements. SAFE HARBOR These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different to performance or achievements expressed. You should not place undue reliance on these statements, since they involve known and unknown risks. Any forward-looking statements reflect the current view with respect to future events and subject to uncertainties. Contact Details Andrew Birnbaum, Chairman/CEO CEO@ADHCINVESTOR.com

May 30, 2023 06:30 AM Eastern Daylight Time

News Release

SNDL discusses factors behind national growth as Canadian cannabis and liquor retailer

SNDL

SNDL CEO Zach George joins Natalie Stoberman from the Proactive newsroom to share how the company has transformed into the largest private-sector retailer for liquor and cannabis in Canada. George says SNDL has been able to attain that national rate of growth because of strategic acquisitions and executing its focus on integration. He adds the company has been able to achieve vertical integration in the Canadian cannabis sector by acquiring businesses like Inner Spirit Holdings, allowing SNDL to expand its retail network to over 365 brick-and-mortar stores. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 29, 2023 01:58 PM Eastern Daylight Time

Video

Creo Medical Group "really pleased" with first human trial of lung lesion treatment

Creo Medical Group PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 26, 2023 11:07 AM Eastern Daylight Time

Video

UAT Group Strategic Partner Next Casting Receives Patent

Umbra Applied Technologies Group, Inc.

Umbra Applied Technologies Group, Inc. (UAT Group) (OTC: UATG ) - UAT Group strategic partner Next Casting Technologies has been issued a patent for technology it developed for use in its advanced SmartCast, IntelliBrace and BioSplint products. Filed in December of 2017, this patent was one of four patents that had been pending. The Company anticipates remaining patents being approved over the next ten to twelve months. Next Casting Technologies (NCT) has begun the process of commercializing proprietary technologies which will positively impact people’s lives and increase value through a unique and diverse product line. The SmartCast Application allows the casting technician to slip the SmartCast around the affected limb and position to ﬁt by using a simple “mold and hold” technique. Lastly, the cast is activated by pressing the button to initiate the curing process. Within 4 minutes that cast is hardened, fixed in place and is not dependent on the technician’s artistry, or lack thereof. The results are a predictable standard of care across the patient spectrum. The end result is a completely waterproof, antimicrobial, orthopedic cast, that is time saving for clinicians and a superior standard of care for patients. UAT Group’s Chief Executive Officer Alex Umbra, stated, “This marks a significant step forward for NCT. Having the appropriate measures in place to protect intellectual property enables the Company to begin evaluating production schedules, supply chain resources and fulfillment execution strategies. I look forward to working with the NCT team in the near-term future as they begin their ramp up.” UAT Group has a 26% equity interest in NCT. For more information about NextCast go here: https://nextorthocast.com/ For more information about UAT go here: http://umbraappliedtechnologies.com/ About Umbra Applied Technologies Group, Inc. The firm is located in Tampa, Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details UAT Group info@uatgroup.com

May 26, 2023 08:00 AM Eastern Daylight Time

Poolbeg Pharma's new NED looking at "new opportunities" for the business

Poolbeg Pharma PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 26, 2023 07:32 AM Eastern Daylight Time

Video

New Products, Growth - USMJ.com Memorial Day Sale

North American Cannabis Holdings, Inc.

North American Cannabis Holdings, Inc. (OTC: USMJ) - USMJ.com a leading cannabis-focused e-commerce site, is thrilled to announce several exciting updates that will delight cannabis enthusiasts across the country. With a commitment to providing high-quality products and exceptional customer service, USMJ continues to be a trusted destination for cannabis enthusiasts nationwide. Remembering and Honoring Our Fallen Heroes: USMJ first and foremost recognizes the significance of Memorial Day and the sacrifices made by our military heroes. In remembrance of those who have selflessly served our nation, USMJ pays tribute to their courage, dedication, and ultimate sacrifice. It is with deep gratitude that USMJ takes this opportunity to honor these fallen heroes and express sincere appreciation for their service. USMJ also provides a special Veterans program with discounts for all who have served. Follow a simple application process to enroll. 20% Off Your Order of $50 or More: USMJ understands the importance of value for its customers. To show appreciation for their continued support, USMJ is offering an exclusive limited-time promotion. Customers can now enjoy a generous discount of 20% on orders totaling $50 or more. This incredible offer allows cannabis enthusiasts to explore a wide range of products while saving on their purchases. The promotion is a week-long and kicked off Wednesday, May 24, 2023, with special notifications delivered to the core customer base ahead of this announcement. The promotion is set to end May 31, 2023, @ 11:59 PM. Use discount code MEM20 at checkout to get 20% off your order. Introducing New Delta 8 Gummies from Wasatch Hemp: USMJ is excited to introduce the latest addition to its product lineup – the highly anticipated Delta 8 Gummies from Wasatch Hemp. These delicious gummies are infused with Delta 8, a hemp-derived cannabinoid known for its unique properties. Crafted with care and precision, the Delta 8 Gummies offer a convenient and enjoyable way to experience the benefits of Delta 8. With Wasatch Hemp's commitment to quality and USMJ's dedication to offering exceptional products, customers can expect nothing short of excellence. Growing Vendor Base and New Products Coming On Board: USMJ is constantly striving to provide an extensive selection of high-quality cannabis products to its customers. To achieve this, USMJ is actively expanding its vendor base and welcoming new products on board. By collaborating with trusted and reputable vendors, USMJ ensures that customers have access to a diverse range of top-tier cannabis products. This commitment to growing the vendor base underscores USMJ's dedication to offering the latest and most innovative products in the industry. USMJ remains dedicated to delivering exceptional customer experiences and upholding the highest standards in the cannabis industry. Through these exciting updates, USMJ aims to provide cannabis enthusiasts with the best products, unbeatable discounts, and an ever-expanding selection of premium offerings. Background: USMJ.com is a line of business of North American Cannabis Holdings, Inc. USMJ.com is one of the largest and fastest-growing marketplaces to shop for CBD, CBG, hemp and cannabis essentials. Additionally, UMSJ.com has multiple B2B programs and partnerships offering them access to the tools and products USMJ.com has to offer. Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For More Information Contact Steven Rash North American Cannabis Holdings, Inc +1 888 694 8765 info@shopusmj.com Contact Details: USMJ info@shopusmj.com Company Website Contact Details USMJ info@shopusmj.com Company Website https://usmj.com/

May 25, 2023 08:45 AM Eastern Daylight Time

News Release

Delivra Health Brands achieves positive EBITDA results for second consecutive quarter

Delivra Health Brands Inc.

Delivra Health Brands President and CEO Gord Davey joins Natalie Stoberman from the Proactive studios to share the how the company's 3Q financial and operational results have been able to repeat positive EBITDA for the second straight quarter. Davey says the company's focus on increasing revenue, reducing costs, and improving margins has been the driver in steady growth and recording a positive EBITDA performance. Davey adds Delivra continues to execute its strategies by expanding its business in the U.S. and international markets, introducing new products in both Dream Water and LivRelief lines, and investing in marketing efforts and ongoing innovation. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

May 24, 2023 02:00 PM Eastern Daylight Time

Video

Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology

TalkMarkets on IKT

Inhibikase Therapeutics ( IKT ) is a small capitalization company working in both neurology and oncology. Their principal focus is a small molecule inhibitor of c-Abl for the treatment of a number of neurodegenerative disorders with an initial focus on Parkinson’s Disease. The lead asset (IkT-148009) is a selective, brain penetrant inhibitor of c-Abl1 and Abl2/ARG. The drug is designed to minimize the toxicity commonly associated with the cancer drugs of this class, while maximizing efficacy against neurological diseases. Neurodegeneration has multiple causes, but the aggregation of misfolded proteins is often associated with these diseases and in the case of Parkinson’s Disease it is the aggregation of alpha-synuclein. Given that these aggregates are clearly associated with the disease, a common tactic to drug development is to find treatments that eliminate the protein bundles, but these approaches have generally had quite modest effects. Inhibikase approaches the disease from a different perspective in that the core issue is when those aggregates become internalized in neurons (in the case of PD). When this occurs, c-Abl triggers a cascade of responses that ultimately leads to neurodegeneration. Inhibiting c-Abl stops these reactions and saves the neurons. (The details of this approach can be seen in the recent article in Neurodegenerative Disease ). One of the difficulties of inhibiting c-Abl in neurodegenerative diseases, however, is the potential toxicity. Gleevec is a commonly used inhibitor of c-Abl in oncology, where it has an acceptable toxicity profile, but it would be too toxic for neurological indications. Developing a drug that can inhibit c-Abl in the brain but without the common toxicities is the fundamental breakthrough of IkT-148009. It is the selectivity of the inhibition that is key. The corporate presentation clearly shows a differentiated inhibition profile ( source ). This selective inhibition of IkT-148009leads to a very clean toxicity profile ( see graphic ). This safety is not simply theoretical as their phase I, Ib, and 2a trials confirm the lack of significant toxicity. There was a grand total of 14 reported adverse events among 113 treated patients and only one was moderate; the rest were mild ( see graphic ). It cannot be stressed enough that safety is absolutely crucial in neurological indications, and it seems that the design of the drug, the preclinical and early clinical results all point to low toxicity, which is exactly what you want to see from these early looks. Inhibikase currently has an ongoing double-blind enrollment trial across three doses for the treatment of Parkinson’s disease. The trial includes a 3-month treatment period followed by a 12-month open label extension. The primary endpoint is safety, which is appropriate for a dose ranging phase II trial and expectations should be a clear confirmation of the established safety profile. That being said, there is a robust set of secondary endpoints that will provide important information as to the efficacy profile. The preclinical work in a Parkinson disease animal model demonstrated a consistent efficacy where treatment lowered alpha-synuclein back to baseline levels, preserved as much as 85% of neurons, restored as much as 90% of motor function, and suppressed neuroinflammation back to near baseline levels. Obviously, a replication of those results in the phase II trial would be spectacular but a clear win would also be a confirmation of the safety profile, a strong signal of efficacy, and a clear move forward dosing level. Given that the PK profile seen in the animal models is similar to the PK shown in the phase I trials, the chosen dosing levels in the phase II trial should lead to a go forward dosing as well as a demonstration of efficacy. The company has guided to a robust set of progress in 2023, where the continued enrollment of the phase II trial is perhaps the most important. Open up to thirty-five 201 trial sites by close of 2Q23 Active screening of commercial formulation Implement 12-month open-label safety extension study into 201 trial Characterize novel compounds as follow-ons to IKT-148009 I noted earlier that Inhibikase Therapeutics is both a neurology and oncology company. In terms of oncology, the company has an improved version of Gleevec that is designed to minimize GI toxicity. This asset is undergoing a bioequivalence trial, which could accelerate the pathway to approval, but I think the key valuation inflection point will be the 201 trial in Parkinson’s disease. The 201 trial has the potential to confirm the safety profile, identify a go-forward dose, and establish efficacy. The current valuation of the company does not reflect any of that potential. It does not even properly reflect the safety profile seen in the phase I trials let alone a potential success in the 201 trial. The heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology. Originally published at TalkMarkets. More By This Author: The FTC, Amgen, And Horizon: A New Hurdle For Biotech Deal Making Or Regulatory Overreach? Coya Therapeutics: Another Success Sarepta: The AdCom Documents Enter The Discussion Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and otherwise represent their own assessments and opinions. Authors are not compensated by the subject companies in any way. This article is also part of our IR Insights Initiative in which articles about participating companies can receive greater visibility. To learn more click here. Contact Details TalkMarkets ir@talkmarkets.com

May 24, 2023 12:04 PM Eastern Daylight Time

ImmuPharma "looking forward with quiet confidence" to FDA response

ImmuPharma PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 24, 2023 11:08 AM Eastern Daylight Time

Video

1 ... 32 33 34 35 36 ... 123